

1 **Malaria species positivity rates among symptomatic individuals across regions of**
2 **differing transmission intensities in Mainland Tanzania**

3 Zachary R. Popkin Hall¹, Misago D. Seth², Rashid A. Madebe², Rule Budodo², Catherine
4 Bakari², Filbert Francis², Dativa Pereus², David J. Giesbrecht³, Celine I. Mandara², Daniel
5 Mbwambo⁴, Sijenunu Aaron⁴, Samwel Lazaro⁴, Jeffrey A. Bailey^{5,6}, Jonathan J. Juliano^{1,#}, Deus
6 S. Ishengoma^{2,7,8,#}

7 ¹Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill,
8 NC, USA 27599

9 ²National Institute for Medical Research, Dar es Salaam, Tanzania

10 ³The Connecticut Agricultural Experiment Station, New Haven, CT, USA 06511

11 ⁴National Malaria Control Programme, Dodoma, Tanzania

12 ⁵Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown
13 University, RI, USA 02906

14 ⁶Center for Computational Molecular Biology, Brown University, RI, USA 02906

15 ⁷Harvard T. H. Chan School of Public Health, Boston, MA 02115

16 ⁸Faculty of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

17 # co-senior authors

18 **Abstract:** Recent data indicate that non-*Plasmodium falciparum* species may be more
19 prevalent than previously realized in sub-Saharan Africa, the region where 95% of the world's
20 malaria cases occur. Although *Plasmodium malariae*, *Plasmodium ovale* spp., and *Plasmodium*
21 *vivax* are generally less severe than *P. falciparum*, treatment and control are more challenging,
22 and their geographic distributions are not well characterized. In order to characterize the
23 distribution of malaria species in Mainland Tanzania (which has a high burden and
24 geographically heterogeneous transmission levels), we randomly selected 3,284 samples from
25 12,845 samples to determine presence and parasitemia of different malaria species. The
26 samples were collected from cross-sectional surveys in 100 health facilities across ten regions
27 and analyzed via quantitative real-time PCR to characterize regional positivity rates for each
28 species. *P. falciparum* was most prevalent, but *P. malariae* and *P. ovale* were found in all
29 regions except Dar es Salaam, with high levels (>5%) of *P. ovale* in seven regions (70%). The
30 highest positivity rate of *P. malariae* was 4.5% in Mara region and eight regions (80%) had
31 positivity rates $\geq 1\%$. We also detected three *P. vivax* infections in the very low-transmission
32 Kilimanjaro region. While most samples that tested positive for non-falciparum malaria were co-
33 infected with *P. falciparum*, 23.6% (n = 13/55) of *P. malariae* and 14.7% (n = 24/163) of *P. ovale*
34 spp. samples were mono-infections. *P. falciparum* remains by far the largest threat, but our data
35 indicate that malaria elimination efforts in Tanzania will require increased surveillance and
36 improved understanding of the biology of non-falciparum species.

37 **Key Words:** malaria, Tanzania, *Plasmodium falciparum*, *Plasmodium malariae*, *Plasmodium*
38 *ovale*, *Plasmodium vivax*

39

40 Introduction:

41 Sub-Saharan Africa (SSA) accounted for 95% of malaria cases and 96% of malaria
42 deaths in 2021[1]. Although *Plasmodium falciparum* is the most prevalent and deadliest human
43 malaria species in the SSA region, four other species are present (*P. vivax*, *P. malariae*, *P.*
44 *ovale curtisi*, and *P. ovale wallikeri*). Furthermore, recent research suggests that these four
45 species are more prevalent than previously thought and their prevalence may increase in the
46 context of intensive *P. falciparum* control/elimination[2–8]. This possibility is particularly salient
47 in light of current malaria elimination goals stemming from the WHO Global Technical
48 Strategy[9], which aims by 2030 to reduce the global malaria burden by 90% from 2015 levels.
49 Non-falciparum malaria species have notably different biology than *P. falciparum* and are not
50 necessarily controlled by the same measures, due to the potential for transmission by different
51 vectors, differing seasonality[10], potentially earlier gametocytogenesis[11–13], presence of
52 hypnozoite stages/persistent infection[12,14], generally lower levels of parasite
53 carriage/density[15,16], and greater asymptomatic infection and transmission[10].


54 *P. vivax* is the most widely distributed human malaria species globally[17]. The strength
55 of Duffy selection with rapid sweep across SSA is testament to the morbidity and mortality that
56 *P. vivax* has caused in the past[18]. Although generally less severe than *P. falciparum*[19], it
57 can be more difficult to control and treat due to the presence of the relapsing hypnozoite stage
58 in the liver[20]. Outside of Africa, e.g., in the Western Pacific, *P. vivax* has increased as *P.*
59 *falciparum* control has succeeded[1]. The prevailing dogma for decades was that *P. vivax* was
60 largely absent from Africa due to high prevalence of the Duffy-negative trait, which is
61 widespread in most SSA populations[21]. However, recent evidence across Africa indicates
62 increased *P. vivax* detection in Duffy-negative patients[22–24]. Nonetheless, it is still much less
63 prevalent than *P. falciparum* and the clinical significance and management strategies of such
64 infections are still unknown.

65 *P. malariae* and *P. ovale* spp. are much less studied than either *P. falciparum* or *P.*
66 *vivax*. They have both been detected throughout Africa, but usually at much lower prevalence
67 than *P. falciparum*[25]. Both are frequently detected in co-infections with *P. falciparum* rather
68 than as mono-infections[15,25–28], although exceptions have been noted[29]. *P. ovale* spp.
69 infections are generally found at low-density, while *P. malariae* infections can cause higher
70 parasitemia[15]. *P. ovale* spp. have relapsing stages like *P. vivax*, which likely means that their
71 control and elimination will be more difficult, as is true of *P. vivax*[12]. *P. malariae* is thought to
72 be more prevalent than *P. ovale*, particularly in West Africa[5,6,14,15]. It does not have a liver
73 stage, but can cause long-term persistent infection[14].

74 While there are data to suggest that non-falciparum malaria is widespread in sub-
75 Saharan Africa[4,26,28,30], and that these prevalences may be increasing[3,5,31], rapid
76 diagnostic tests (RDTs) currently deployed in Africa are better at detecting falciparum malaria
77 than other species[32,33]. Given the preponderance of both low-density infections and multiple
78 species co-infections with non-falciparum malaria species, as well as the lower likelihood of
79 severe disease, these species are less likely to be detected during surveillance activities or at
80 the point-of-care. While molecular diagnostics such as qPCR are readily capable of detecting
81 both falciparum and non-falciparum *Plasmodium* spp., these tools are highly technical and
82 resource-prohibitive, so are rarely used outside of laboratory research activities.

83 Tanzania has the third highest malaria burden in the world, accounting for 4.1% of global
84 malaria deaths in 2021[1]. Malaria transmission in Tanzania is predominantly *P. falciparum* and
85 highly heterogeneous by region and season (**Figure 1A**)[34]. Transmission is high and endemic
86 along the coast and the Lake Zone, and low, unstable, and seasonal in large urban areas and
87 highland regions, while the rest of the country is subject to moderate seasonal transmission[34].

88 Previous work has looked at prevalence of non-falciparum malaria among asymptomatic
89 school children, finding surprisingly high rates of *P. ovale* spp. infection[8]. However, data from
90 symptomatic cases for Tanzania is based primarily on sporadic convenience samples and does
91 not provide broad geographic information about the distribution of non-falciparum malaria. To
92 address the distribution of non-falciparum malaria in symptomatic individuals from all age
93 groups, we conducted a survey of symptomatic malaria cases across ten different regions of
94 Mainland Tanzania with varying transmission intensity. We present a molecular analysis of
95 malaria species positivity rates within this national dataset.



96
97 **Figure 1 – A)** National map of regional malaria prevalence in 2021 as determined by a combination of blood slide
98 positivity rates and *Pfhrp2*/LDH mRDT positivity rates. Data courtesy of National Malaria Control Programme,
99 Dodoma. **B)** Map of Tanzania highlighting study regions.

100

101 **Methods:**

102 *Ethics:*

103 The Molecular Surveillance of Malaria in Tanzania (MSMT) study protocol was approved by the
104 Tanzanian Medical Research Coordinating Committee (MRCC) of the National Institute for
105 Medical Research (NIMR) and involved approved standard procedures for informed consent
106 and sample deidentification. Additional details are described elsewhere[35]. Deidentified
107 samples were considered non-human subjects' research at the University of North Carolina and
108 Brown University. In addition, publicly available aggregate data on malaria prevalence from all
109 regions of Tanzania was provided by the National Malaria Control Programme (NMCP) for 2021
110 in order to map regional malaria prevalence.

111 *Sample collection:*

112 A random subset of 3,284 samples were drawn from 12,845 samples collected during
 113 the MSMT project[35] in 2021. Briefly, samples were collected in the MSMT *Plasmodium*
 114 *falciparum* histidine-rich protein 2 and 3 (*Pfhrp2/3*) gene deletion survey in ten regions: Dar es
 115 Salaam, Dodoma, Kagera, Kilimanjaro, Manyara, Mara, Mtwara, Njombe, Songwe, and
 116 Tabora[35], with additional samples collected in these regions for population genetic studies of
 117 malaria parasites. Additional details on study site selection are given in Rogier *et al.*[35].
 118 Surveys were conducted according to the WHO protocol[36] and included ten regions (**Figure**
 119 **1B**) which are distributed across mainland Tanzania with variable malaria transmission levels.
 120 Regions were assigned to four transmission strata ranging from very low to high based on
 121 NMCP data from 2020[34] (**Table 1**).

122 *Table 1 – Summary of study regions and number of samples analyzed*

Region	Transmission Strata	Samples
Kilimanjaro	Very Low	897
Manyara	Very Low	223
Njombe	Very Low	211
Subtotal	Very Low	1,331
Dar es Salaam	Low	213
Dodoma	Low	274
Songwe	Low	145
Subtotal	Low	632
Mara	Moderate	335
Tabora	Moderate	267
Subtotal	Moderate	602
Kagera	High	417
Mtwara	High	302
Subtotal	High	719
Overall	All	3,284

123
 124 Dried blood spots (DBS) were collected from patients with malaria-like symptoms. Most
 125 individuals (n = 3,234) were tested with a standard Pfhrp2/ pan-*Plasmodium* lactate
 126 dehydrogenase (pLDH) mRDT while some (n = 1,942) were also administered a PfLDH-based
 127 mRDT[35]. Samples were considered malaria-positive if any mRDT was positive.

128 *Molecular speciation assays:*

129 DNA from three 6mm DBS punches[37], representing approximately 25 µl of blood[8]
 130 was extracted using Chelex into a final usable volume of approximately 100 µl. Quantitative real
 131 time PCR assays targeting the 18S ribosomal subunit were performed according to published
 132 protocols (Supplemental Table 1)[28]. A separate qPCR assay was run for each species: *P.*
 133 *falciparum*, *P. malariae*, *P. ovale* spp. (detecting both *P. o. curtisi* and *P. o. wallikeri*), and *P.*
 134 *vivax*. Detection and parasitemia quantification were based on standard curves generated using
 135 dilutions of plasmids from MR4 (MRA-177, MRA-178, MRA-179, MRA-180; BEI Resources,
 136 Manassas, VA). Plasmids were quantified using a Qubit fluorometer, then normalized to a
 137 standard concentration of 0.1 ng/µL before serial dilutions. Three ten-fold dilution concentrations
 138 (0.001 ng/µL, 0.0001 ng/µL, 0.00001 ng/µL) were used for qPCR standard curves. Semi-
 139 quantitative parasitemia was estimated based on the assumption of six 18S rRNA gene copies
 140 per parasite genome[28], then multiplied by four to account for the dilution of eluted DNA
 141 relative to initial blood volume[8]. *P. malariae* assays used 42 cycles, while all other assays

142 used 45 cycles to detect low-density infections[28]. This approach has been previously validated
143 as highly sensitive and specific[28,38].

144 *Statistical analysis:*

145 Positivity rates were calculated for each region, as the data are biased toward
146 individuals with both clinical symptoms and mRDT positivity and therefore do not represent true
147 prevalence inclusive of asymptomatic infections. Regional-level maps of positivity rate for each
148 species were created using the R package *sf* (version 1.0-9) based on shape files available
149 from GADM.org and naturalearthdata.com accessed via the R package *naturalearth* (version
150 0.3.2)[39].

151 Variation in species-specific positivity rates by region, transmission strata, individuals'
152 age, and age group (young children <5 years, school-aged children 5-16 years[8,40], and adults
153 >16 years) was assessed for significance with generalized linear models or ANOVA, as
154 appropriate, in R. Given there is no consensus for an age range for school aged children, we
155 used the age range of the 2017 Tanzania National School Children Survey[8,40].

156 **Results:**

157 *Study Population:*

158 Within this subset of 3,284 patients, the median age was 12 (IQR 3–28) years with a range
159 of 6 months to 87 years. Children (≤ 16 years old) constituted 56.4% of participants ($n = 1,853$),
160 while adults (>16 years old) constituted the remaining 43.6% ($n = 1,431$). Young children (<5
161 years old) comprised 58.3% ($n = 1,081$) of the child participants, while the remaining 41.7% ($n =$
162 772) were school-aged (5 – 16 years old). Gender identifications were available for 3,196
163 participants and female-skewed, with 1,754 female (54.9%) and 1,442 male participants (45.1%).
164 Sample sizes for each region are given in **Table 1**. 53.7% ($n = 1,763$) of sampled individuals
165 tested positive by any mRDT.

166 *qPCR Positivity by Species:*

167 Across all individuals sampled, *P. falciparum* was detected in 56.8% ($n = 1,865$, 95% CI:
168 55.1% – 58.5%), *P. malariae* in 1.7% ($n = 55$, 95% CI: 1.3% – 2.2%), *P. ovale* spp. in 5.0% ($n =$
169 163, 95% CI: 4.3% – 5.8%), and *P. vivax* in 0.09% ($n = 3$, 95% CI: 0.02% – 0.2%).

170 Mixed-species infections were common (**Table 2**). The majority of *P. malariae* infections
171 were mixed with *P. falciparum* (56.4%, $n = 31$), although *P. malariae* mono-infections were also
172 common (23.6%, $n = 13$), as were three-species infections with *P. malariae*, *P. falciparum* and
173 *P. ovale* spp (18.2%, $n = 10$). The vast majority of *P. ovale* spp. infections were also mixed with
174 *P. falciparum* (78.5%, $n = 128$, **Table 2**). As with *P. malariae*, single-species infections occurred and
175 were more common than either three-species infections or mixed infection with *P. ovale* and
176 *P. malariae* only. Of the three *P. vivax* infections detected, all were mixed with *P. falciparum* (**Table**
177 **2**). This small sample size precluded further statistical analyses.

178

179

180

181

Table 2 – Infection composition proportions for non-falciparum infections

Infection Type	Count	Proportion
<i>Pm</i>	13	23.6%
<i>Pm/Pf</i>	31	56.4%
<i>Pm/Po</i>	1	1.8%
<i>Pm/Pf/Po</i>	10	18.2%
All <i>Pm</i> Infections	55	
<i>Po</i>	24	14.7%
<i>Po/Pf</i>	128	78.5%
<i>Pm/Po</i>	1	0.6%
<i>Pm/Pf/Po</i>	10	6.1%
All <i>Po</i> Infections	163	
<i>Pv</i>	0	0%
<i>Pv/Pf</i>	3	100%
All <i>Pv</i> Infections	3	

182

*Sum of proportions may not equal 100% due to rounding.

183

Parasite Density:

184


185 Parasitemia as determined by semi-quantitative qPCR based on standard dilutions of
186 plasmid varied significantly (ANOVA $p < 0.001$) by species, with *P. falciparum* parasitemia the
187 highest at median (IQR) 1,226,000 p/μL (23,280 – 13,090,000 p/μL), followed by *P. malariae* at
188 389,920 p/μL (19,364 – 2,147,000 p/μL), and *P. ovale* spp. having the lowest median parasitemia
189 at 3,970 p/μL (396 – 54,000 p/μL). A Tukey post hoc test detected a significant difference in
190 parasitemia ($p < 0.001$) between *P. falciparum* and *P. ovale* spp., but not between the other
191 species pairs. Parasitemia did not differ significantly between single and mixed-species infections
192 (Supplemental Figure 1). The three *P. vivax* infections (parasitemia of 70, 4,704, and 61,400 p/μL)
were not analyzed.

193

Variability by Region and Transmission Strata:

194

195 *P. falciparum* was detected in every region sampled (**Figure 2A**) with variable positivity
196 rates (**Table 3**). *P. malariae* and *P. ovale* spp. were detected in every region except for Dar es
Salaam (**Figure 2B, 2C**). *P. vivax* was only detected in Kilimanjaro region (**Figure 2D**).



197
 198 **Figure 2 – Species positivity rate maps across Tanzania for A) *P. falciparum*, B) *P. malariae*, C) *P. ovale* spp., and D)**
 199 ***P. vivax*. Shaded regions represent only positivity rates among health facility samples and should not be assumed**
 200 **to represent true regional prevalences.**


201

202

Table 3 – Positivity Rates by Region

Region	Pf Positive Samples	Pm Positive Samples	Po Positive Samples	Pv Positive Samples	Total Samples
Dar es Salaam	161 (75.6%)	0 (0%)	0 (0%)	0 (0%)	213
Dodoma	174 (63.5%)	5 (1.8%)	15 (5.5%)	0 (0%)	274
Kagera	261 (62.6%)	13 (3.1%)	24 (5.8%)	0 (0%)	417
Kilimanjaro	209 (23.3%)	2 (0.2%)	4 (0.4%)	3 (0.3%)	897
Manyara	144 (64.6%)	3 (1.4%)	14 (6.3%)	0 (0%)	227
Mara	240 (71.6%)	15 (4.5%)	51 (15.2%)	0 (0%)	335
Mtwara	238 (78.8%)	3 (1.0%)	10 (3.3%)	0 (0%)	302
Njombe	124 (58.8%)	6 (2.8%)	15 (7.1%)	0 (0%)	211
Songwe	93 (64.1%)	3 (2.1%)	14 (9.7%)	0 (0%)	145
Tabora	221 (82.8%)	5 (1.9%)	16 (6.0%)	0 (0%)	267

203 *P. falciparum* was most abundant in Tabora (82.8%, n = 221/267, **Table 3**) and Mtwara
 204 (78.8%, n = 238/302), while it was least abundant in Kilimanjaro (23.3%, n = 209/897). *P. malariae*
 205 was most abundant in Mara (4.5%, n = 15/335) and Kagera (3.1%, n = 13/417) and least abundant
 206 in Kilimanjaro (0.2%, n = 2/897) and Mtwara (1.0%, n = 3/302). *P. ovale* spp. positivity rates
 207 surpassed 5% in seven regions, with the highest abundance in Mara (15.2%, n = 51/335), Songwe
 208 (9.7%, n = 14/145), and Njombe (7.1%, n = 15/211). It was rare in Kilimanjaro (0.4%, n = 4/897).
 209 In all ten regions, *P. ovale* positivity rates were higher than *P. malariae*. Positivity rates varied
 210 significantly by region for all three species (ANOVA p < 0.001). Overall, transmission strata had
 211 a highly significant (ANOVA p < 0.001) effect on the positivity rates of all three species. Tukey
 212 post hoc analysis between strata is shown in **Figure 3**.




213
 214 **Figure 3** – Tukey Analysis of Malaria Species Positivity Rate by Transmission Strata. A total of 1,331, 632, 602, and
 215 719 samples were available in the very low, low, medium, and high transmission strata, respectively. The number of
 216 positive samples per strata for each species is shown in the X-axis labels. Level of significance is shown as follows: *
 217 p<0.05, ** p<0.01, *** p<0.001, or **** p<0.0001. Panel A shows *P. falciparum* parasite rates by strata. There were
 218 significant differences between most strata in pairwise comparison, therefore the only nonsignificant comparison is
 219 shown (NS). Panel B shows the *P. malariae* parasite rate by strata. Pairwise comparisons of strata with significant
 220 differences in parasite rate are shown (*). Panel C shows *P. ovale* spp. parasite rate by strata. Pairwise comparisons
 221 of strata with significant differences in parasite rate are shown (*).

222
 223 Transmission strata had a significant effect on the likelihood of *P. falciparum* co-infection
 224 by ANOVA (p = 0.002) for *P. ovale* spp. A Tukey post hoc test indicated 24.6% (95% CI: 2.5% –
 225 46.7%) fewer co-infections in very low vs. high transmission strata (p = 0.02) as well as 28.9%
 226 (95% CI: 0.97% – 48.1%) fewer co-infections in very low vs. moderate strata (p < 0.001). There
 227 was also a nearly significant (p = 0.06) reduction in co-infections between the very low and low
 228 transmission strata. By contrast, there was no significant effect on the likelihood of *P. malariae*
 229 co-infection with *P. falciparum*.

230 Variability by Age Group

231 No significant difference in *P. malariae* prevalence by age in years was detected (GLM p
 232 = 0.24). In contrast to *P. malariae*, age significantly correlated with *P. ovale* spp. infection (GLM
 233 p = 0.001). Children had significantly more *P. ovale* spp. infections (6.5%, n = 120/1,853) than

234 adults (3.0%, n = 43/1,431). When splitting participants into three age groups (**Figure 4**), overall
 235 significant correlations by ANOVA were observed with qPCR positivity for *P. falciparum* ($p <$
 236 0.001), *P. malariae* ($p = 0.004$), and *P. ovale* spp. ($p < 0.001$) (**Figure 4**). For *P. falciparum*, a
 237 Tukey post hoc test indicated significant variation ($p < 0.001$) between young children (<5 years),
 238 school children (5 - 16 years), and adults (>16 years), with children more likely to be positive than
 239 adults and school children more likely to be positive than young children. School children were
 240 also more likely to be positive for *P. malariae* than either adults ($p = 0.003$) or young children (p
 241 $= 0.03$), but no significant differences were detected between young children and adults. For *P.*
 242 *ovale* spp., school children were again more likely to test positive than either adults ($p < 0.001$) or
 243 young children ($p = 0.04$), and young children were more likely to test positive than adults ($p =$
 244 0.01).



245
 246 **Figure 4 – Tukey Analysis of Malaria Species Positivity Rate by Age Strata.** A total of 1,081, 772, and 1,413
 247 individuals were in the Young Children (<5 years), School Children (5-16 years) and Adult (>16 years) strata,
 248 respectively. The number of positive samples per age strata for each species is shown in the X-axis labels. Level of
 249 significance is shown as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, or **** $p < 0.0001$. **Panel A** shows *P. falciparum*
 250 parasite rates by age strata. Pairwise comparisons of strata with significant differences in parasite rate are shown. All
 251 other pairwise comparisons were nonsignificant. **Panel B** shows the *P. malariae* parasite rate by strata. Pairwise
 252 comparisons of strata with significant differences in parasite rate are shown. All other pairwise comparisons were
 253 nonsignificant. **Panel C** shows *P. ovale* spp. parasite rate by strata. Pairwise comparisons of strata with significant
 254 differences in parasite rate are shown. All other pairwise comparisons were nonsignificant.

255
 256 **Discussion:**

257 This study presents a comprehensive picture of the geographic distribution of different
 258 malaria species among symptomatic patients within Mainland Tanzania across all ages and in
 259 different transmission strata. It establishes a snapshot of the epidemiological landscape in 2021
 260 that will enable effective longitudinal tracking of non-falciparum malaria. *Plasmodium falciparum*
 261 remains by far the most prevalent malaria species in Tanzania. Nonetheless, *P. malariae* and
 262 especially *P. ovale* spp. are much more abundant than previously acknowledged, with multiple
 263 regions approaching or surpassing (in the case of *P. ovale* spp.) 5% positivity rates. *P. vivax* is
 264 rarely detected and was found only in Kilimanjaro.

265 Our findings support a recent report of high rates of *P. ovale* infection among
266 asymptomatic school aged children in 2017[8]. Direct comparison between the studies is not
267 possible due to the significant methodological differences (e.g. clinic-based symptomatic versus
268 school-based asymptomatic). However, we see predominately low density *P. ovale* infections
269 that are over-represented in the school aged individuals in this study. Though the 2017 study
270 identified *P. ovale* spp. primarily as mono-infections[8], we identified mostly mixed infections
271 with *P. falciparum* (**Table 2**). This discrepancy is most likely explained by our inclusion of
272 symptomatic patients in the study, as infection with *P. falciparum* likely led them to seek medical
273 care, while school children with *P. ovale* spp. mono-infections are more likely to be
274 asymptomatic[15]. Indeed, they constitute a major asymptomatic infectious reservoir[41–43].

275 The relatively high (> 5%) *P. ovale* spp. positivity rates in seven regions point to the
276 necessity of active surveillance for these species, particularly given data from Tanzania and
277 elsewhere showing increased incidence[3,5,7,31]. As was seen by the 2017 study[8], we found
278 *P. ovale* spp. mono-infections to be more frequent in areas of low *P. falciparum* transmission,
279 even though our samples came from symptomatic patients reporting to health facilities. The
280 presence of these infections suggests that measures developed for *P. falciparum* will not
281 completely control malaria in these regions. Since *P. ovale* spp. develops hypnozoites which
282 can cause relapse, and which are not treated by standard schizonticidal regimens[12], its
283 control is more complicated than that of *P. falciparum*. While major aspects of its biology,
284 including major vectors, are poorly understood, transmission may be seasonal and
285 asynchronous with *P. falciparum*[10]. Proactive monitoring will allow the NMCP and other
286 decision makers to regularly monitor incidence and implement *P. ovale*-specific control
287 measures as appropriate to support malaria control and elimination efforts.

288 While *P. malariae* was less abundant than *P. ovale* spp. in our study, it is nonetheless
289 present throughout Tanzania and also warrants regular surveillance. We identified few
290 significant differences in *P. malariae* positivity by transmission strata and no effect of
291 transmission strata on likelihood of co-infection with *P. falciparum*, but these results may stem
292 from small sample sizes (55 total *P. malariae* infections and 13 mono-infections). The relatively
293 low *P. malariae* levels detected in our study are also consistent with those found in other
294 surveys of Tanzania as well as Malawi and Western Kenya[8,28,44]. Taken together, these
295 results suggest that *P. malariae* is less of a concern than *P. ovale* spp. in East Africa. However,
296 transmission of *P. malariae*, like *P. ovale* spp., has been noted to increase as *P. falciparum*
297 transmission reduces throughout East Africa[2,3,5,16]. If these trends continue and both
298 species become more abundant, effective malaria control will increasingly hinge upon their
299 surveillance.

300 While there was significant regional variation in *P. malariae* and *P. ovale* spp.
301 abundance in our study, it did not consistently correspond with transmission strata defined by *P.*
302 *falciparum* data. In both *P. malariae* and *P. ovale* spp., the moderate transmission strata had the
303 highest positivity rate, largely stemming from the high rates of both in Mara region. While *P.*
304 *malariae* was equally likely to be co-infected with *P. falciparum* in all transmission strata, *P.*
305 *ovale* spp. was more likely to occur as a single-species mono-infection in the very low
306 transmission strata.

307 Based on our data, *P. vivax* remains a minimal concern in Tanzania. However, as with
308 the other species, its incidence could increase as *P. falciparum*'s decreases and like *P. ovale*
309 spp., it would require specialized treatment and control measures. Other studies have also

310 detected *P. vivax* at low levels in Kagera, Mara, and Mwanza[8,45], the coastal regions of
311 Mtwara and Tanga[8], and on the Zanzibar archipelago[16,46]. The fact that we did not detect
312 *P. vivax* in multiple regions is consistent with its characteristically low prevalence of $\leq 1\%$.
313 Because of its low prevalence, more intensive and targeted surveillance will be necessary to
314 understand the biology of *P. vivax* in Tanzania, but its clinical impact is likely minor compared to
315 the other species.

316 Case-based surveillance pilots targeting malaria elimination have been implemented
317 within the very low transmission regions of Kilimanjaro and Manyara, with the goal of expanding
318 to other very low transmission regions[47]. While our results suggest that non-falciparum
319 species are present at low prevalence within Kilimanjaro, and therefore unlikely to present major
320 barriers to elimination in that region, Manyara has *P. ovale* spp. positivity rates $> 5\%$, meaning
321 that elimination efforts within that region will need to account for the specific surveillance,
322 treatment, and control challenges presented by this species. Standardized treatment protocols
323 currently employed in Tanzania do not incorporate “radical cure” with primaquine or tafenoquine
324 to treat the liver-stage hypnozoites that cause relapses in *P. ovale* spp.[48]. As such, while ACT
325 treatment may clear blood-stage parasites, relapses will continue to occur.

326 This study has several limitations. Given the sampling scheme of using only people
327 presenting to the clinic with symptoms (whether they had mRDT-positive malaria or not) we are
328 unable to determine true prevalence rates for each species and report parasite rate. This is due
329 to the fact that mRDT-positive individuals are likely over-enrolled and the asymptomatic
330 reservoir is not sampled. The addition of community surveys could help alleviate this.
331 Parasitemia estimates are also relative given the use of plasmids as the control and a multi-
332 copy gene for detection. Better controls are needed for accurate quantification of non-falciparum
333 malaria using molecular methods. Lastly, while encompassing large regions of the country, the
334 survey is not fully nationally representative and misses one crucial pre-elimination area,
335 Zanzibar, where data on non-falciparum malaria may be very beneficial for elimination plans.

336 Non-falciparum malaria, particularly *P. ovale* spp. and *P. malariae*, is present throughout
337 mainland Tanzania. In order to achieve effective control and elimination of malaria, it will be
338 necessary to conduct further surveillance and research on these species. Ongoing research as
339 part of MSMT will enable both longitudinal epidemiological study and genomic characterization
340 of the non-falciparum malaria landscape in Tanzania, as nationwide samples from 2022 and
341 2023 will be available, allowing a fuller picture of the abundance of *P. malariae*, *P. ovale* spp.,
342 and *P. vivax* within Tanzania, as well as an indication of temporal trends that are not detectable
343 in the work presented here. In addition, efforts to sequence high parasitemia *P. malariae* and *P.*
344 *ovale* spp. samples collected in 2021 are ongoing and will grant us a deeper and more
345 comprehensive picture of the Tanzanian populations of these species.

346 **Acknowledgements:** The authors wish to thank participants and parents/guardians of all children
347 who took part in the surveillance. We acknowledge the contribution of the following project staff
348 and other colleagues who participated in data collection and/or laboratory processing of samples:
349 Raymond Kitengeso, Ezekiel Malecela, Muhidin Kassim, Athanas Mhina, August Nyaki, Juma
350 Tupa, Anangisye Malabeja, Emmanuel Kessy, George Gesase, Tumaini Kamna, Grace
351 Kanyankole, Oswald Osca, Richard Makono, Ildephonse Mathias, Godbless Msaki, Rashid
352 Mtumba, Gasper Lugela, Gineson Nkya, Daniel Chale, Richard Malisa, Sawaya Msangi, Ally
353 Idrisa, Francis Chambo, Kusa Mchaina, Neema Barua, Christian Msokame, Rogers Msangi,
354 Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusa, Jumaa Akida, Ambele

355 Yatinga, and Tilaus Gustav. We also acknowledge the finance, administrative and logistic support
356 team at NIMR: Christopher Masaka, Millen Meena, Beatrice Mwampeta, Gracia Sanga, Neema
357 Manumbu, Halfan Mwanga, Arison Ekoni, Twalipo Mponzi, Pendaël Nasary, Denis Byakuzana,
358 Alfred Sezary, Emmanuel Mnzava, John Samwel, Daud Mjema, Seth Nguhu, Thomas Semdoe,
359 Sadiki Yusuph, Alex Mwakibinga, Rodrick Ulomi and Andrea Kimboi. We are also grateful to the
360 management of the National Institute for Medical Research, National Malaria Control Program
361 and President's Office-Regional Administration and Local Government (regional administrative
362 secretaries of the 14 regions, and district officials, staff from all 100 HFs and Community Health
363 Workers from the 4 community cross sectional regions). Technical and logistics support from the
364 Bill and Melinda Gates Foundation team is highly appreciated. The following reagents were
365 obtained through BEI Resources, NIAID, NIH: Diagnostic Plasmid Containing the Small Subunit
366 Ribosomal RNA Gene (18S) from *Plasmodium falciparum*, MRA-177; *Plasmodium vivax*, MRA-
367 178; *Plasmodium malariae*, MRA-179; and *Plasmodium ovale*, MRA-180, contributed by Peter A.
368 Zimmerman.

369

370 **Funding**

371 This work was supported, in whole, by the Bill & Melinda Gates Foundation [grant number
372 002202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0
373 Generic License has already been assigned to the Author Accepted Manuscript version that might
374 arise from this submission. JJJ also received funding from NIH K24AI134990.

375

376 **Data availability:** National malaria transmission data was provided by the National Malaria
377 Control Programme in Dodoma and is available by contacting NMCP. All other data is available
378 upon reasonable request to the corresponding author.

379 **References:**

- 380 1. World Health Organization. World malaria report 2022. Geneva; 2022.
- 381 2. Akala HM, Watson OJ, Mitei KK, et al. Plasmodium interspecies interactions during a
382 period of increasing prevalence of *Plasmodium ovale* in symptomatic individuals seeking
383 treatment: an observational study. The Lancet Microbe [Internet]. **2021** [cited 2022 Mar
384 31]; 2(4):e141–e150. Available from:
385 <https://linkinghub.elsevier.com/retrieve/pii/S2666524721000094>
- 386 3. Betson M, Clifford S, Stanton M, Kabatereine NB, Stothard JR. Emergence of
387 Nonfalciparum *Plasmodium* Infection Despite Regular Artemisinin Combination Therapy
388 in an 18-Month Longitudinal Study of Ugandan Children and Their Mothers. J Infect Dis
389 [Internet]. Oxford Academic; **2018** [cited 2022 Mar 31]; 217(7):1099–1109. Available
390 from: <https://academic.oup.com/jid/article/217/7/1099/4791878>
- 391 4. Mitchell CL, Topazian HM, Brazeau NF, et al. Household Prevalence of *Plasmodium*
392 *falciparum*, *Plasmodium vivax*, and *Plasmodium ovale* in the Democratic Republic of the
393 Congo, 2013–2014. Clin Infect Dis [Internet]. Oxford University Press (OUP); **2020** [cited
394 2021 Mar 17]; . Available from: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1772/6006303)
395 [article/doi/10.1093/cid/ciaa1772/6006303](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1772/6006303)
- 396 5. Yman V, Wandell G, Mutemi DD, et al. Persistent transmission of *Plasmodium malariae*
397 and *Plasmodium ovale* species in an area of declining *Plasmodium falciparum*
398 transmission in eastern Tanzania. Marks F, editor. PLoS Negl Trop Dis [Internet]. Public
399 Library of Science; **2019** [cited 2021 Apr 19]; 13(5):e0007414. Available from:
400 <https://dx.plos.org/10.1371/journal.pntd.0007414>

- 401 6. Nguiffo-Nguete D, Nongley Nkemngo F, Ndo C, et al. *Plasmodium malariae* contributes
402 to high levels of malaria transmission in a forest–savannah transition area in Cameroon.
403 Parasites Vectors 2023 161 [Internet]. BioMed Central; **2023** [cited 2023 Jan 30];
404 16(1):1–10. Available from:
405 <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05635-7>
- 406 7. Sendor R, Banek K, Kashamuka MM, et al. Epidemiology of *Plasmodium malariae* and
407 *Plasmodium ovale* spp. in a highly malaria-endemic country: a longitudinal cohort study in
408 Kinshasa Province, Democratic Republic of Congo. medRxiv [Internet]. Cold Spring
409 Harbor Laboratory Press; **2023** [cited 2023 May 2]; :2023.04.20.23288826. Available
410 from: <https://www.medrxiv.org/content/10.1101/2023.04.20.23288826v1>
- 411 8. Sendor R, Mitchell CL, Chacky F, et al. Similar Prevalence of *Plasmodium falciparum* and
412 Non-*P. falciparum* Malaria Infections among Schoolchildren, Tanzania. Emerg Infect Dis
413 [Internet]. **2023**; 29(6):1143–1153. Available from:
414 https://wwwnc.cdc.gov/eid/article/29/6/22-1016_article
- 415 9. World Health Organization. Global Technical Strategy for Malaria 2016-2030 [Internet].
416 Geneva; 2015. Available from:
417 <https://www.who.int/malaria/publications/atoz/9789241564991/en/>
- 418 10. Tarimo BB, Nyasembe VO, Ngasala B, et al. Seasonality and transmissibility of
419 *Plasmodium ovale* in Bagamoyo District, Tanzania. Parasit Vectors [Internet]. BioMed
420 Central; **2022** [cited 2022 Feb 16]; 15(1):56. Available from:
421 <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05181-2>
- 422 11. Bousema T, Drakeley C. Epidemiology and Infectivity of *Plasmodium falciparum* and
423 *Plasmodium vivax* Gametocytes in Relation to Malaria Control and Elimination. Clin
424 Microbiol Rev [Internet]. **2011**; 24(2):377–410. Available from:
425 <https://journals.asm.org/doi/10.1128/CMR.00051-10>
- 426 12. Collins WE, Jeffery GM. *Plasmodium ovale*: Parasite and disease. Clin Microbiol Rev
427 [Internet]. American Society for Microbiology; **2005** [cited 2022 Mar 31]; 18(3):570–581.
428 Available from: <https://journals.asm.org/doi/full/10.1128/CMR.18.3.570-581.2005>
- 429 13. Holzschuh A, Gruenberg M, Hofmann NE, et al. Co-infection of the four major
430 *Plasmodium* species: Effects on densities and gametocyte carriage. PLoS Negl Trop Dis
431 [Internet]. Public Library of Science; **2022** [cited 2023 Sep 12]; 16(9):e0010760. Available
432 from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010760>
- 433 14. Oriero EC, Amenga-Etego L, Ishengoma DS, Amambua-Ngwa A. *Plasmodium malariae*,
434 current knowledge and future research opportunities on a neglected malaria parasite
435 species. Crit Rev Microbiol [Internet]. Taylor & Francis; **2021** [cited 2021 Jan 29]; 0(0):1–
436 13. Available from:
437 <https://www.tandfonline.com/doi/full/10.1080/1040841X.2020.1838440>
- 438 15. Roucher C, Rogier C, Sokhna C, Tall A, Trape JF. A 20-Year Longitudinal Study of
439 *Plasmodium ovale* and *Plasmodium malariae* Prevalence and Morbidity in a West African
440 Population. PLoS One [Internet]. Public Library of Science; **2014** [cited 2023 Mar 24];
441 9(2):e87169. Available from:
442 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087169>
- 443 16. Cook J, Xu W, Msellem M, et al. Mass Screening and Treatment on the Basis of Results
444 of a *Plasmodium falciparum*-Specific Rapid Diagnostic Test Did Not Reduce Malaria

- 445 Incidence in Zanzibar. *J Infect Dis* [Internet]. Oxford Academic; **2015** [cited 2022 Mar 31];
446 211(9):1476–1483. Available from:
447 <https://academic.oup.com/jid/article/211/9/1476/854482>
- 448 17. Battle KE, Baird JK. The global burden of *Plasmodium vivax* malaria is obscure and
449 insidious. Seidlein L von, editor. *PLOS Med* [Internet]. Public Library of Science; **2021**
450 [cited 2021 Oct 8]; 18(10):e1003799. Available from:
451 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003799>
- 452 18. McManus KF, Taravella AM, Henn BM, Bustamante CD, Sikora M, Cornejo OE.
453 Population genetic analysis of the DARC locus (Duffy) reveals adaptation from standing
454 variation associated with malaria resistance in humans. *PLOS Genet* [Internet]. Public
455 Library of Science; **2017** [cited 2023 Aug 7]; 13(3):e1006560. Available from:
456 <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006560>
- 457 19. Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W.
458 Severe vivax malaria: A systematic review and meta-analysis of clinical studies since
459 1900. *Malar J* [Internet]. BioMed Central Ltd.; **2014** [cited 2023 Mar 24]; 13(1):1–10.
460 Available from: <https://link.springer.com/articles/10.1186/1475-2875-13-481>
- 461 20. Schäfer C, Zanghi G, Vaughan AM, Kappe SHI. *Plasmodium vivax* Latent Liver Stage
462 Infection and Relapse: Biological Insights and New Experimental Tools. *Annu Rev*
463 *Microbiol* [Internet]. Annual Reviews; **2021** [cited 2021 Jul 7]; 75(1):87–106. Available
464 from: <https://www.annualreviews.org/doi/abs/10.1146/annurev-micro-032421-061155>
- 465 21. Howes RE, Patil AP, Piel FB, et al. The global distribution of the Duffy blood group. *Nat*
466 *Commun* [Internet]. **2011**; 2(1):266. Available from:
467 <https://www.nature.com/articles/ncomms1265>
- 468 22. Leang R, Taylor WRJ, Bouth DM, et al. Evidence of *Plasmodium falciparum* Malaria
469 Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia:
470 Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. *Antimicrob*
471 *Agents Chemother* [Internet]. American Society for Microbiology; **2015** [cited 2021 Jul
472 16]; 59(8):4719–4726. Available from: <https://journals.asm.org/doi/10.1128/AAC.00835-15>
- 474 23. Auburn S, Getachew S, Pearson RD, et al. Genomic Analysis of *Plasmodium vivax* in
475 Southern Ethiopia Reveals Selective Pressures in Multiple Parasite Mechanisms. *J Infect*
476 *Dis* [Internet]. Oxford University Press; **2019** [cited 2021 Jun 23]; 220(11):1738–1749.
477 Available from: <https://academic.oup.com/jid/article/220/11/1738/5298331>
- 478 24. Twohig KA, Pfeffer DA, Baird JK, et al. Growing evidence of *Plasmodium vivax* across
479 malaria-endemic Africa. *PLoS Negl Trop Dis* [Internet]. Public Library of Science; **2019**
480 [cited 2022 Aug 11]; 13(1):e0007140. Available from:
481 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007140>
- 482 25. Sutherland CJ. Persistent Parasitism: The Adaptive Biology of Malariae and *Ovale*
483 *Malaria*. *Trends Parasitol* [Internet]. Elsevier Current Trends; **2016** [cited 2023 Mar 24];
484 32(10):808–819. Available from:
485 <https://linkinghub.elsevier.com/retrieve/pii/S147149221630099X>
- 486 26. Mitchell CL, Brazeau NF, Keeler C, et al. Under the Radar: Epidemiology of *Plasmodium*
487 *ovale* in the Democratic Republic of the Congo. *J Infect Dis* [Internet]. **2021** [cited 2020
488 Aug 11]; 223(6):1005–1014. Available from: <https://academic.oup.com/jid/advance->


- 489 [article/doi/10.1093/infdis/jiaa478/5885064](https://doi.org/10.1093/infdis/jiaa478/5885064)
- 490 27. Mueller I, Zimmerman PA, Reeder JC. *Plasmodium malariae* and *Plasmodium ovale* –
491 the ‘bashful’ malaria parasites. Trends Parasitol [Internet]. **2007**; 23(6):278–283.
492 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1471492207000906>
- 493 28. Gumbo A, Topazian HM, Mwanza A, et al. Occurrence and Distribution of Nonfalciparum
494 Malaria Parasite Species Among Adolescents and Adults in Malawi. J Infect Dis
495 [Internet]. Oxford Academic; **2022** [cited 2023 Mar 27]; 225(2):257–268. Available from:
496 <https://academic.oup.com/jid/article/225/2/257/6318237>
- 497 29. Sendor R, Mitchell CL, Chacky F, et al. Non-falciparum malaria infections are as
498 prevalent as *P. falciparum* among Tanzanian schoolchildren. medRxiv [Internet]. Cold
499 Spring Harbor Laboratory Press; **2022** [cited 2023 May 2]; :2022.06.07.22275625.
500 Available from: <https://www.medrxiv.org/content/10.1101/2022.06.07.22275625v1>
- 501 30. Mbama Ntabi JD, Lissom A, Djontu JC, et al. Prevalence of non-*Plasmodium falciparum*
502 species in southern districts of Brazzaville in The Republic of the Congo. Parasit Vectors
503 [Internet]. BioMed Central; **2022** [cited 2022 Jun 23]; 15(1):209. Available from:
504 <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05312-9>
- 505 31. Hawadak J, Dongang Nana RR, Singh V. Global trend of *Plasmodium malariae* and
506 *Plasmodium ovale* spp. malaria infections in the last two decades (2000–2020): a
507 systematic review and meta-analysis. Parasites and Vectors [Internet]. BioMed Central
508 Ltd; **2021** [cited 2023 May 2]; 14(1):1–14. Available from:
509 <https://link.springer.com/articles/10.1186/s13071-021-04797-0>
- 510 32. World Health Organization. Malaria Rapid Diagnostic Test Performance. Geneva: World
511 Health Organization; 2009.
- 512 33. Yerlikaya S, Campillo A, Gonzalez IJ. A Systematic Review: Performance of Rapid
513 Diagnostic Tests for the Detection of *Plasmodium knowlesi*, *Plasmodium malariae*, and
514 *Plasmodium ovale* Mono-infections in Human Blood. J Infect Dis [Internet]. Oxford
515 Academic; **2018** [cited 2023 Mar 24]; 218(2):265–276. Available from:
516 <https://academic.oup.com/jid/article/218/2/265/4938977>
- 517 34. National Malaria Control Programme. Malaria Surveillance Bulletin - 2022. Malar. Surveill.
518 Bull. Dodoma; 2022.
- 519 35. Rogier E, Battle N, Bakari C, et al. Plasmodium falciparum pfrp2 and pfrp3 gene
520 deletions among patients enrolled at 100 health facilities throughout Tanzania: February
521 to July 2021. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; **2023** [cited 2023
522 Aug 7]; :2023.07.29.23293322. Available from:
523 <https://www.medrxiv.org/content/10.1101/2023.07.29.23293322v1>
- 524 36. World Health Organization (WHO). Master protocol for surveillance of pfrp2. 2020.
- 525 37. Plowe C V., Djimdé A, Bouaré M, Doumbo O, Wellems TE. Pyrimethamine and Proguanil
526 Resistance-Confering Mutations in *Plasmodium falciparum* Dihydrofolate Reductase:
527 Polymerase Chain Reaction Methods for Surveillance in Africa. Am J Trop Med Hyg.
528 **1995**; 52(6):565–568.
- 529 38. Brazeau NF, Mitchell CL, Morgan AP, et al. The epidemiology of *Plasmodium vivax*
530 among adults in the Democratic Republic of the Congo. Nat Commun 2021 121 [Internet].
531 Nature Publishing Group; **2021** [cited 2021 Jul 9]; 12(1):1–10. Available from:

- 532 <https://www.nature.com/articles/s41467-021-24216-3>
- 533 39. Massicotte P, South A. naturalearth: World Map Data from Natural Earth [Internet]. 2023.
534 Available from: <https://cran.r-project.org/package=rnaturalearth>
- 535 40. Mitchell CL, Ngasala B, Janko MM, et al. Evaluating malaria prevalence and land cover
536 across varying transmission intensity in Tanzania using a cross-sectional survey of
537 school-aged children. *Malar J* [Internet]. BioMed Central; **2022** [cited 2022 Mar 11];
538 21(1):80. Available from:
539 <https://malariajournal.biomedcentral.com/articles/10.1186/s12936-022-04107-8>
- 540 41. Abdulraheem MA, Ernest M, Ugwuanyi I, et al. High prevalence of *Plasmodium malariae*
541 and *Plasmodium ovale* in co-infections with *Plasmodium falciparum* in asymptomatic
542 malaria parasite carriers in southwestern Nigeria. *Int J Parasitol* [Internet]. Pergamon;
543 **2022** [cited 2023 May 4]; 52(1):23–33. Available from:
544 <https://linkinghub.elsevier.com/retrieve/pii/S0020751921002393>
- 545 42. Andolina C, Rek JC, Briggs J, et al. Sources of persistent malaria transmission in a
546 setting with effective malaria control in eastern Uganda: a longitudinal, observational
547 cohort study. *Lancet Infect Dis* [Internet]. Elsevier; **2021** [cited 2021 Jul 12]; 21(11):1568–
548 1578. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1473309921000724>
- 549 43. Walldorf JA, Cohee LM, Coalson JE, et al. School-Age Children Are a Reservoir of
550 Malaria Infection in Malawi. *PLoS One* [Internet]. Public Library of Science; **2015** [cited
551 2023 May 4]; 10(7):e0134061. Available from:
552 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134061>
- 553 44. Lo E, Nguyen K, Nguyen J, et al. *Plasmodium malariae* Prevalence and *csp* Gene
554 Diversity, Kenya, 2014 and 2015 - Volume 23, Number 4—April 2017 - Emerging
555 Infectious Diseases journal - CDC. *Emerg Infect Dis* [Internet]. Centers for Disease
556 Control and Prevention (CDC); **2017** [cited 2023 May 4]; 23(4):601–610. Available from:
557 https://wwwnc.cdc.gov/eid/article/23/4/16-1245_article
- 558 45. Kim MJ, Jung BK, Chai JY, et al. High Malaria Prevalence among Schoolchildren on
559 Kome Island, Tanzania. *Korean J Parasitol* [Internet]. The Korean Society for
560 Parasitology and Tropical Medicine; **2015** [cited 2023 May 4]; 53(5):571–574. Available
561 from: <http://www.parahostdis.org/journal/view.php?doi=10.3347/kjp.2015.53.5.571>
- 562 46. Msellem M, Kemere J, Mårtensson A, et al. Prevalence of PCR Detectable Malaria
563 Infection among Febrile Patients with a Negative *Plasmodium falciparum* Specific Rapid
564 Diagnostic Test in Zanzibar. *Am J Trop Med Hyg* [Internet]. **2013**; 88(2):289–291.
565 Available from: <https://ajtmh.org/doi/10.4269/ajtmh.2012.12-0095>
- 566 47. U.S. President’s Malaria Initiative. Tanzania (Mainland) Malaria Operational Plan FY
567 2023. 2023.
- 568 48. Groger M, Veletzky L, Lalremruata A, et al. Prospective Clinical and Molecular Evaluation
569 of Potential *Plasmodium ovale curtisi* and *walikeri* Relapses in a High-transmission
570 Setting. *Clin Infect Dis* [Internet]. Oxford Academic; **2019** [cited 2023 May 4];
571 69(12):2119–2126. Available from:
572 <https://academic.oup.com/cid/article/69/12/2119/5486976>
- 573
- 574

575 Supplemental Table 1 – qPCR Reactions

576 (uploaded as separate Excel sheet)

577



578

579 Supplemental Figure 1 – Parasitemia for Mixed Infections with *P. falciparum* vs. Single-Species Mono-Infections for
580 A) *P. malariae* and B) *P. ovale* spp. No significant difference was detected between mixed and mono-infections.